GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » EV-to-EBIT

Aprinoia Therapeutics (Aprinoia Therapeutics) EV-to-EBIT : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Aprinoia Therapeutics's Enterprise Value is $0.00 Mil. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-20.18 Mil. Therefore, Aprinoia Therapeutics's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Aprinoia Therapeutics's EV-to-EBIT or its related term are showing as below:

APRI's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.19
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Aprinoia Therapeutics's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-20.18 Mil. Aprinoia Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.

Aprinoia Therapeutics EV-to-EBIT Historical Data

The historical data trend for Aprinoia Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics EV-to-EBIT Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
EV-to-EBIT
- -

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
EV-to-EBIT - - - -

Competitive Comparison of Aprinoia Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Aprinoia Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's EV-to-EBIT falls into.


Aprinoia Therapeutics EV-to-EBIT Calculation

Aprinoia Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-20.178
=0.00

Aprinoia Therapeutics's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-20.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics  (NAS:APRI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Aprinoia Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-20.178/0
= %

Aprinoia Therapeutics's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-20.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » EV-to-EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines